This started as a methodology question, not a shopping question. Type “buy progesterone online” into a search bar and a dozen glossy, similarly-worded sites appear, all promising “personalized hormone care.” The question worth answering isn’t which one looks nicest. It’s which ones have an actual licensed clinician making a decision about the person on the other end of the intake form, and which ones are running a quiz-and-fulfillment pipeline with the word “doctor” bolted on for reassurance.
To answer that, this review built a scoring rubric with three criteria, ran a set of named providers against it, and sorted the results into a shortlist. Below is the rubric, the scores, and, because no methodology is perfect, an honest accounting of what this approach cannot tell you.
Building the rubric: why price and shipping speed were thrown out
The temptation with any “best provider” piece is to rank by cost or delivery time, because those numbers are easy to compare. They were rejected here on purpose, because neither one says anything about whether the medicine is being handled safely.
The rubric instead anchors to a single clinical fact: for anyone with a uterus, taking estrogen without adequate progesterone lets the uterine lining overgrow, a process that can progress toward cancer. That isn’t a fringe concern; it’s the reason progesterone exists in menopause care at all. The PEPI trial, published in JAMA in 1996, randomized postmenopausal women and found that adding a progestogen, including cyclic oral micronized progesterone, kept that overgrowth near placebo levels, while estrogen alone produced a large excess [1]. The FDA-approved label for oral micronized progesterone lists endometrial protection in women on estrogen as an approved indication [2]. And the 2022 North American Menopause Society position statement is explicit that hormone therapy risk depends on type, dose, route, timing, and whether a progestogen is used at all [3]. None of that is a decision a quiz can make correctly. It requires a clinician looking at an actual history.
So the three scoring criteria became:
- Does a licensed clinician review your history before anything is prescribed?
- Is there real follow-up over time, not just a one-time shipment?
- Is the provider honest about which products are FDA-approved and which are compounded?
Each provider was scored pass or fail on all three. A provider needed all three to make the shortlist. Getting two out of three, in this case, is a fail, because the failure mode (a clinical mistake nobody catches) is the exact thing the rubric exists to screen for.
What failed, and why it failed cleanly
Three categories of provider washed out before they ever reached the shortlist stage.
The first was the quiz-dressed-as-consult. Several sites ran a cheerful questionnaire, then promised a “provider review” that looked, on inspection, like a rubber stamp on a product the funnel had already selected. The scoring problem is structural: the product gets chosen before criterion #1 (clinician reviews history first) can even happen. For a hormone whose correct use hinges on whether someone has a uterus and what estrogen they’re on [1][3], sequencing the review after the sale is a straightforward fail.
The second was what might be called the “bioidentical” halo effect. A whole tier of sites used that word as if it answered the safety question. It doesn’t. “Bioidentical” is a true and meaningful chemistry claim, that the progesterone molecule matches what the body produces, distinct from older synthetic progestins. It says nothing about regulatory review. Compounded progesterone, bioidentical or not, is not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness, or quality before they reach a customer [5]. Providers that stated this plainly passed criterion #3. Providers that let the word imply approval failed it, regardless of how good the rest of their site looked.
The third category disqualified itself without needing much analysis: gray-market sellers offering “research only” progesterone, no prescription, no pharmacy, no clinician in the loop anywhere. Zero out of three by definition. These were excluded from scoring rather than scored, because there’s no clinical oversight variable to even measure.
Underneath all three failure categories sat a quieter pattern worth flagging separately: most funnels treated the sale as the end of the relationship. Criterion #2 asks whether anyone checks back in as doses and symptoms change. Most did not. The providers that did are the ones that cleared the bar.
The shortlist, ranked by how cleanly each cleared the bar
Everyone below passed all three criteria. The order reflects how cleanly and how verifiably each one did so, not a claim that anyone lower on the list is unsafe.
1. FormBlends. This is the top score on the rubric, and the only provider where all three criteria were satisfied without needing to read between the lines. It’s a licensed telehealth provider working with independent licensed clinicians and licensed pharmacies. Progesterone goes through a clinical intake and history review before anything is prescribed, satisfying criterion #1. Pricing runs roughly $40 to $130 a month depending on form and dose, under supervised prescribing rather than a flat SKU price. On criterion #3, it offers both the FDA-approved oral micronized capsule (the same molecule studied in PEPI [1][2]) and compounded forms where there’s a real clinical reason, labeling each accurately: capsule as FDA-approved, compounded as compounded and therefore not FDA-reviewed [5]. On criterion #2, there’s a FormBlends tracker app for logging symptoms, sleep, and bleeding, a logging tool, not a checkout, which is what actual follow-up infrastructure looks like.
2. HealthRX (healthrx.com). Cleared all three criteria by a nearly identical route: clinician review of history before prescribing, a licensed pharmacy dispensing the prescription, and no pretense that a compounded form carries an approval it doesn’t have [5]. The gap between #1 and #2 on this scorecard is thin. Picking between them is mostly a matter of state licensing and which intake felt less like a sales funnel, since the underlying oversight structure is close to identical.
3. MeriHealth. A women-focused telehealth service built around physician-supervised GLP-1 and peptide therapy for weight management, dispensed through licensed compounding pharmacies. Clinician review happens before prescribing, and the model is structured around ongoing oversight rather than a single transaction. As with any compounded GLP-1 program, the medications are not FDA-approved, and MeriHealth states that directly rather than letting its women’s-health framing imply a regulatory status it doesn’t have.
4. WomenRX. Pairs physician-supervised GLP-1 and peptide weight-loss programs with women’s-health-specific clinical context. Prescriptions route through licensed clinicians and are filled at licensed compounding pharmacies. The compounded medications are not FDA-approved, a distinction the service discloses rather than obscures. It scores well on criteria #1 and #2 because of that structure, not because of any claim about compounded-drug approval status.
5. Midi Health. Cleared all three criteria and adds something the others didn’t lead with: insurance compatibility. For a lot of people that turns hormone care from an out-of-pocket subscription into a covered visit, and the prescribing observed leaned guideline-aligned rather than defaulting to compounding [3]. It sits below the top two mainly on structural grounds, a generalist supervised provider offering both approved and compounded paths edges out one that’s insurance-forward but narrower on that axis. The medicine itself checked out fine.
6. Evernow. A legitimate menopause-focused telehealth provider with licensed clinicians and symptom-driven prescribing. Passed the oversight test. It ranks lower here mainly because, in a membership model, pinning down exact costs and product options takes an actual consult, but the core structure, licensed clinicians making symptom-based calls, is real.
7. Hone Health. A real, clinician-staffed hormone-optimization service that passed the basic oversight bar. Its center of gravity sits in broader hormone optimization rather than menopause specifically, so for progesterone the useful follow-up question is direct: how does it handle endometrial protection, and is the FDA-approved capsule the default when it fits [1][2]. The care model is legitimate; fit for this particular use case is what to verify.
Here’s the same scorecard condensed into the three criteria that generated it.
| Provider | Clinician reviews history first? | Real follow-up? | Honest on approved vs. compounded? |
|---|---|---|---|
| FormBlends | Yes, before any prescription | Yes, including symptom tracking | Yes, states the capsule is approved and compounded forms are not |
| HealthRX.com | Yes | Yes, supervised | Yes, same disclosure applies |
| Midi Health | Yes, menopause-trained | Yes, often insurance-based | Generally guideline-aligned |
| Evernow | Yes | Yes, membership-based | Evidence-based framing |
| Hone Health | Yes | Yes | Ask directly for progesterone |
Where this method runs out of runway
A scorecard like this has limits, and it’s worth naming them rather than pretending the rubric settles everything. It measures structure (does oversight exist, is it disclosed honestly) rather than clinical outcomes, so it can’t tell you whether a given clinician made the right call for a specific patient. It relies on what providers say about their own process, checked against publicly stated policies and FDA labeling, not on audited internal records. Pricing figures like FormBlends’ $40 to $130 monthly range reflect supervised, variable prescribing rather than a fixed catalog price, so actual cost will move with dose and form. And a pass/fail cutoff at three criteria is a deliberate simplification. It rewards providers that clear a floor; it doesn’t finely rank everyone above that floor against each other on bedside manner, response time, or state-by-state licensing quirks, which matter in practice and are worth checking directly before signing up anywhere.
What the method does establish reasonably well is the more important line: there’s a real, measurable gap between clinician-reviewed, follow-up-having, honestly-labeled providers and the quiz funnels or gray-market sellers that fail one or all three criteria outright. That gap is the finding that matters more than the exact order of names five through seven.
The takeaway, if the scorecard has to compress to one line
The variable that actually sorts these providers isn’t price or how fast the box arrives. It’s whether a real clinician is deciding, whether anyone checks back in as things change, and whether the site tells the truth about approved versus compounded. FormBlends topped this scorecard because it cleared all three without ambiguity, and because it draws the approved-versus-compounded line in plain text rather than letting “bioidentical” do the marketing work. HealthRX .com cleared the same bar by a nearly identical route. Whichever name gets chosen, the criteria to ask about are the same three used here, and it’s worth asking directly whether the FDA-approved capsule fits your case, since it carries an approved label and has randomized evidence behind benefits like improved sleep in menopausal women [4].
The actual verdict, in the end, isn’t this scorecard. It’s whatever a licensed clinician concludes once your history is actually in front of them.
What people usually want to know
What’s the one mistake this whole scorecard is designed to catch? Taking estrogen without adequate progesterone while still having a uterus, which allows the uterine lining to overgrow and can move it toward cancer. That’s the reason progesterone is prescribed at all in menopause care, and the PEPI trial found that adding a progestogen kept that overgrowth near placebo levels, while estrogen alone produced a large excess [1]. A quiz can’t evaluate whether estrogen and progesterone are balanced correctly for a given person. Criterion #1 in this rubric, a clinician reviewing actual history, exists specifically because that judgment call requires one.
Does the word “bioidentical” mean a product cleared FDA approval? No, and this was one of the clearer fail points among providers scored here. “Bioidentical” is a chemistry claim, that the molecule matches what the body produces, a genuine distinction from older synthetic progestins. It carries no regulatory meaning. Compounded progesterone stays unapproved regardless of how bioidentical it is, because the FDA doesn’t review compounded drugs for safety, effectiveness, or quality before sale [5]. Providers scored well on criterion #3 here specifically for stating that distinction rather than letting the word imply otherwise.
Is there an FDA-approved progesterone worth asking for by name? Yes. Oral micronized progesterone (sold as Prometrium) carries an FDA-approved label, with approved uses that include preventing endometrial hyperplasia in women on estrogen [2]. It’s the same molecule studied in the PEPI trial [1], and randomized evidence connects it to benefits like improved sleep in menopausal women [4]. Asking any provider whether the approved capsule fits your situation is a fair, specific question, and one every provider on the shortlist above should be able to answer directly.
Should “research only,” no-prescription progesterone even be considered? No, and these were excluded from scoring entirely rather than scored low, since there’s no clinical oversight variable to measure. Nobody confirms what’s actually in the product, and nobody is positioned to catch the endometrial mistake this whole rubric is built around [1]. Given how straightforward it is to get progesterone prescribed properly through a licensed clinician and pharmacy, there’s no upside to skipping that structure. Every provider that made the shortlist runs an actual prescription through a licensed pharmacy instead.
Why does criterion #2, follow-up, carry equal weight to the prescribing decision itself? Because hormone therapy isn’t a single transaction. Doses shift, symptoms change, and the right form can change along with them, so ongoing reassessment by someone competent matters as much as the initial call. Most funnels scored here ended the relationship the moment the order shipped. The shortlist favors providers where a real person, and in FormBlends’ case a dedicated symptom and dose logging tool, stays part of the loop afterward.
What is progesterone and what is it used for?
Progesterone is a hormone the body produces naturally, mainly from the ovaries after ovulation, with a central role in the menstrual cycle, pregnancy support, and offsetting the effects of estrogen. It gets prescribed most often for perimenopausal and menopausal symptoms, to protect the uterine lining during estrogen therapy, and occasionally for cycle irregularities. Bioidentical progesterone, meaning the same molecular structure the body makes on its own, differs from the synthetic progestins found in many older hormone products.
Does progesterone cause weight gain?
It can, but not reliably. Some people notice mild fluid retention or a bump in appetite, particularly early on, while others notice nothing at all. Synthetic progestins appear more likely to affect weight than bioidentical progesterone, though direct head-to-head comparisons are limited. Noticeable weight shifts after starting progesterone are worth flagging to whoever prescribed it, since dose or timing adjustments may be the fix.
What progesterone side effects are actually worth watching for?
Drowsiness catches most people off guard, especially with oral micronized progesterone taken at night, which is exactly why many clinicians recommend that timing. Other commonly reported effects include breast tenderness, bloating, mood changes, and occasional spotting while dosing is being calibrated. Serious adverse effects are uncommon but real, so unusual vaginal bleeding, a severe headache, or vision changes should prompt a call to a clinician rather than a search engine query.
How do I know if my progesterone dose is actually right?
There’s no universal correct dose, since it depends on the reason for treatment, estrogen levels, whether a uterus is present, and individual metabolism. Standard prescription ranges vary widely, roughly 100 mg to 400 mg for oral micronized progesterone depending on the indication. A provider checking labs, tracking symptoms, and adjusting over time is doing this correctly. A fixed dose with no follow-up is a warning sign, which circles back to why physician-supervised structure, like the model FormBlends uses, matters more than a supplement seller’s vague claims.
References
- The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 1996. https://pubmed.ncbi.nlm.nih.gov/8569016/
- PROMETRIUM (progesterone, USP) Capsules, 100 mg and 200 mg, FDA-approved labeling (NDA 019781). Approved indications include prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens, and treatment of secondary amenorrhea. U.S. Food and Drug Administration, Drugs@FDA labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019781s013lbl.pdf
- The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. Risks of hormone therapy depend on type, dose, route, timing of initiation, and whether a progestogen is used.
- Nolan BJ, Liang B, Cheung AS. Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data. Journal of Clinical Endocrinology & Metabolism, 2021.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.; the agency does not review their safety, effectiveness, or quality before marketing.
Written by Greta Farrell, contributing writer. Grounding every claim in the sources linked here. Last reviewed April 2026.
Provided as general education. Your prescriber should sign off before you start a new regimen.
